Meng Hua

·.: 、,.:1993 -1998,.2000,.2004,.2005-2007.:1993-1997,2000 11,2004 10.2002-2003,.2005-2007.2007 2017, 、,,2009,2010.2011 2,.2015 11.2017 3.2017 9 “ ”,2020,.:, 、, 2011. 7000,, 5000 、 、. 100 、. 2016 “ ”.2017 12 (IGCC),2021.::1.Guangyong,Huajin,ChunpanZhang,MengH,XinyanZhao,DanWei,XiaojuanOu,QianyiWang,ShuxiangLi,TianqiWang,1XiaojingSun,WenShi,DanTian,KaiLiu,HufengXu,YueTian,XinminLi,WeiGuo,JidongJia,ZhongtaoZhangandDongZhang,OX40RegulatesBothInnateandAdaptiveImmunityandPromotesNonalcoholicSte-atohepatitis,CellReports25,3786-3799,December26,2018. 2.MengH,ZhangZT,Multielementsofmedicalcaringingastriccancer.,ChineseMedicalJournal,2014.4.01,127(3):401~402. 3.MengH,WangX,FongY,WangZH,WangY,ZhangZT,Outcomesofradicalsur-geryforgallbladdercancerpatientswithlymphaticmetastases.,JpnJClinOncol.,2011.8.01,41(8):2~8. 4.MengH,Tanigawa,Nobuhiko,Hao,Chun-Yi,Dai,De-Jian,Lu,Cai-De,Ji,Jia-Fu,Chemoresponsetodocetaxelcorrelateswithexpressionofthesurvivinsplicingvariantsinpa-tientswithgastriccancer.,Hepatogastroenterology,2007.01.01,54(79):1934~1940. 5.MengHua,Lu,Caide,Mabuchi,Hideaki,Tanigawa,Nobuhiko,Prognosticsignificanceanddifferentpropertiesofsurvivinsplicingvariantsingastriccancer.,CancerLett,2004.12.28,216(2):147~155. 6.MengHua,Lu,Cai-De,Sun,Yu-Lei,Dai,De-Jian,Lee,Sang-Wong,Tanigawa,No-buhiko,Expressionlevelofwild-typesurviviningastriccancerisanindependentpredictorofsurvival.,WorldJGastroenterol,2004.11.15,10(22):3245~3250. 7.,,,, ( 14 ),,2016.1.20,(01):36~40. 8.,,,, +Roux-en-Y 2,,2016.1.20, (01):24~26. 9.,,,Survivin,,2005.01.01,8(3)234-236. 10.,,,,, survivin,,2004.01.01,84(24)2060-2063. 11.,,,, 、,,2004.01.01,24(8)484-487.: 1.NaLi,HuaMeng.serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunction-associatedfattyliverdis-ease.FrontPhysiol.2021Jul22;12:696163.doi:10.3389/fphys.2021.696163. 2.XiaohuiLi,HiaLiu,BiaoZhou,YinhuiLi,ZhengyuWu,HuaMeng,GuangWang.Sexdif-ferencesintheeffectoftestosteroneonadiposetissueinsulinresistancefromoverweighttoobeseadults.JClinEndocrinolMetab.2021Jul13;106(8):2252-2263.doi:10.1210/clinem/dgab325. 3.QinQ,ShouJ,LiM,GuM,ShouJ,MengZ,XuP,MengH&WangX*.Stk24protectsagainstobesity-associatedmetabolicdisordersbydisruptingtheNLRP3inflammasome.CellReports.2021May25.ISSN2211-1247. 4.LiuJ,WangQ,ZhangL,FuJ,AnY,MengH,WangG.IncreasedProlactinisanAdaptiveResponsetoProtectAgainstMetabolicDisordersinObesity.EndocrPract.2021Jan15:S1530-891X(21)00007-0.doi:10.1016/j.eprac.2021.01.002. 5.HuangC,WangQ,ZhangQ,ZhouB,LinJ,MengH.EffectsofRoux-en-YGastricBypassandSleeveGastrectomyonBoneMineralDensityinZuckerDiabeticFattyRats:AShort-TermComparativeStudy.ObesFacts.2021Mar4:1-12.doi:10.1159/000514426. 6.ZhouBiao,HuaMeng.ERASreducespostoperativehospitalstayandcomplicationsafterbar-iatricsurgery:aretrospectivecohortstudy.Accepted.2021. 7.GuangxingMeng,QianzheXing,QiangYuan,ZhiDu,YijunWang,HuaMeng,Inter- nalcomparedwithexternaldrainageofpancreaticductduringpancreaticoduodenectomy:aretrospectivestudy.,ChineseJournalofCancerResearch,2014.6.01,26(3):77~84. 8.Liu,Ping,Sun,Yu-Lei,Du,Jie,Hou,Xiao-Sai,MengHua,CD105/Ki67coexpression correlateswithtumorprogressionandpoorprognosisinepithelialovariancancer.,IntJGy-necolCancer,2012.5.01,22(4):586~592. 9.,,,..,2020,35(8):653-654. 10.,,,,. 2.,2020,35(7):569-570. 11.,,,. Meta.,2019,18(22):2432-2435. 12.,,,. meta.,2019,41(2):139-143. 13.,,,,,,. 3.,2019,18(9):854-858. 14.,.. 2019 24 6,474-477. 15.,.BMI<35Kg/m2 [J].,2018,4(3):156-159 16.,,. 2 [J].,2018,45(8):556-560. 17.,,. π Roux-en-Y.,2018,17(6),626-6230. 18.,..,2018,33(12):1025. 1)《 》..2006,; 2)《 》..2006,; 3)::ZL202020013270.7 4):;ZL202020013254.8: 、,.: 2016 “ ”.